A Phase 3 interventional study of Lapatinib and Trastuzumab in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Completed at 110 sites in 29 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.
Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 13th largest by enrollment, is one of 8 that started in 2011, is one of 18 in phase 3, and was the 81st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 70 · Phase 3 18
First in 2003; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 369 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 35 across the 114 interventional studies. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 33rd largest by enrollment of the 155 interventional ones that give a count, is one of 4 that started in 2011, is one of 45 in phase 3, and was the 69th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 114 studies testing lapatinib in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).
This Phase III, multicenter, open-label study randomized subjects to one of the three treatment arms:
Treatment continued until disease progression, death, or unacceptable toxicities, whichever came first.
Subjects who discontinued study treatment for reasons other than disease progression were followed-up every 12 weeks until disease progression or death, until the start of post-study treatment anti-cancer therapy (including radiotherapy and surgery), withdrawal of consent, or lost to follow-up, whichever came first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects eligible for enrollment in the study must meet all of the following criteria:
female subjects >=18 years of age. Post-menopausal as defined by any of the following:
Documentation of overexpression or gene amplification, in the invasive component of either the primary tumor or metastatic disease site as defined as:
Subject must have received at least one prior regimen containing trastuzumab in combination with chemotherapy for breast cancer:.
Exclusion criteria:
Serious cardiac illness or medical condition including but not confined to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lapatinib 1000 mg PO once daily + Trastuzumab (loading dose of 8 mg/kg) followed by the maintenance dose of 6 mg/kg IV every 3 weeks (q3weeks) + an Aromatase Inhibitor (AI) of Investigator's choice PO once daily.
Drug: Lapatinib · Drug: Trastuzumab · Drug: Aromatase Inhibitor
Trastuzumab (loading dose of 8 mg/kg) followed by maintenance dose of 6 mg/kg IV every 3 weeks (q3weeks) + an Aromatase Inhibitor (AI) of Investigator's choice PO once daily.
Drug: Trastuzumab · Drug: Aromatase Inhibitor
Lapatinib 1500 mg PO once daily + an Aromatase Inhibitor (AI) of Investigator's choice PO once daily.
Drug: Aromatase Inhibitor · Drug: Lapatinib
1000 mg by mouth once a day
Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks (q3weeks)
Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
1500 mg by mouth once daily
This study also gives Anastrozole, Exemestane. No intervention listed here names it: that was found by reading the record.
Progression Free Survival (PFS) Events in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)
The Number of Participants with Progression free survival (PFS) events in the Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) arm vs. Trastuzumab + Aromatase Inhibitor (AI) arm was based on assessments by the Investigator.
Time frame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 5 years
Median Kaplan Meier Estimates for PFS in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)
Progression free survival (PFS) was defined as the interval of time between the date of randomization and the earliest date of disease progression (with radiological evidence) or death from any cause, or to the date of censor. Disease progression was based on assessments by the Investigator.
Time frame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 5 years
Progression Free Survival (PFS)
Progression free survival (PFS) was defined as the interval of time between the date of randomization and the earliest date of disease progression (with radiological evidence) or death from any cause, or to the date of censor. Disease progression was based on assessments by the Investigator.
Time frame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 11 years
Overall Survival (OS)
The Number of Participants with Overall Survival (OS) events was based on assessments by the Investigator.
Time frame: From date of randomization until date of death from any cause, assessed up approximately 11 years
Overall Response Rate (ORR)
Overall Response Rate (ORR) was defined as the proportion of participants achieving either a Complete Response (CR) or Partial Response (PR). The ORR was calculated from the Investigator's assessment of response based on RECIST 1.1. Subjects with an unknown or missing response were treated as non-responders; i.e. they were included in the denominator when calculating the percentages. Subjects who do not have measurable disease contributed to the Response Rate based analyses, for the evaluation of CR, SD and PD.
Time frame: Up approximately 11 years
Clinical Benefit Rate (CBR)
Clinical Benefit Rate (CBR) was defined as the percentage of patients with evidence of Complete Response (CR), Partial Response (PR), or maintaining Stable Disease (SD) for at least 6 months while on study, according to the investigator assessment of response per RECIST 1.1 criteria.
Time frame: Up approximately 11 years
Time to Response
Time to Response (TTR) was defined as the time from randomization to the earliest date of Complete Response (CR) or Partial Response (PR)
Time frame: From date of randomization until the earliest date of Complete Response (CR) or Partial Response (PR), assessed up approximately 11 years
Duration of Response (DoR)
Duration of Response (DOR) was defined as the duration between the date of first documented Complete Response (CR) or Partial Response (PR) and the date of first documented sign of Progressive Disease or Death, or to the date of censor.
Time frame: From first documented evidence of CR or PR (the response prior to confirmation) until time of documented disease progression or death due to any cause, whichever comes first, assessed up approximately 11 years
Mean Change in the Quality of Life (QoL) Status Relative to Baseline FACT-B Overall and Subscale Scores at Last On Treatment Assessment
Quality of life was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire. It is a 37-item (27 general questions and 10 breast cancer specific questions) self-reporting instrument consisting of 5 dimensions: physical well-being (PWB), social well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and a breast cancer subscale (BCS). The followings were the score ranges for each self-reporting subscale: • PWB : 0-28 • SWB : 0-28 • EWB : 0-24 • FWB : 0-28 • BCS : 0-40 FACT-B Total Outcome Index (TOI) = PWB + FWB + BCS (range:0 - 96) FACT-B Total Score = PWB + SWB + EWB + FWB + BCS (range:0-148) FACT-G Total Score = PWB + SWB + EWB + FWB (range:0-108). For all the FACIT scales and symptom indices, the higher the score the better QoL
Time frame: Day 1 (pre-dose), up approximately 11 years
This study was conducted at 113 centers in 29 countries worldwide (Argentina, Australia, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Peru, Poland, Portugal, Republic of Korea, Russia, Serbia, Singapore, Spain, Taiwan, Turkey, UK, Ukraine and USA)
| Milestone | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|---|
| Started | 124 | 123 | 122 |
| Safety set | 123 | 123 | 121 |
| Completed | 64 | 64 | 55 |
| Not completed | 60 | 59 | 67 |
| Withdrew: Subject reached protocol-defined stopping criteria | 49 | 49 | 59 |
| Withdrew: Lost to follow-up | 4 | 8 | 4 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 | 2 |
| Withdrew: Data unavailable due to regulatory issues | 2 | 0 | 2 |
The Number of Participants with Progression free survival (PFS) events in the Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) arm vs. Trastuzumab + Aromatase Inhibitor (AI) arm was based on assessments by the Investigator.
| Participants | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|
| Disease progression or died (event) | 62 | 75 |
| Censored, follow-up for disease progression ended | 7 | 3 |
| Censored, f/p for disease progression ongoing | 51 | 39 |
Progression free survival (PFS) was defined as the interval of time between the date of randomization and the earliest date of disease progression (with radiological evidence) or death from any cause, or to the date of censor. Disease progression was based on assessments by the Investigator.
| Months | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|
| Median Kaplan Meier Estimates for PFS in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI) | 11.0 (8.3 to 13.8) | 5.6 (5.4 to 8.3) |
Progression free survival (PFS) was defined as the interval of time between the date of randomization and the earliest date of disease progression (with radiological evidence) or death from any cause, or to the date of censor. Disease progression was based on assessments by the Investigator.
| Months | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|---|
| Progression Free Survival (PFS) | 11.1 (10.0 to 15.3) | 8.3 (7.1 to 11.0) | 5.7 (5.5 to 8.3) |
The Number of Participants with Overall Survival (OS) events was based on assessments by the Investigator.
| Participants | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|---|
| Death | 38 | 45 | 39 |
| Censored, follow-up ended | 86 | 78 | 83 |
| Censored, follow-up ongoing | 0 | 0 | 0 |
Overall Response Rate (ORR) was defined as the proportion of participants achieving either a Complete Response (CR) or Partial Response (PR). The ORR was calculated from the Investigator's assessment of response based on RECIST 1.1. Subjects with an unknown or missing response were treated as non-responders; i.e. they were included in the denominator when calculating the percentages. Subjects who do not have measurable disease contributed to the Response Rate based analyses, for the evaluation of CR, SD and PD.
| Percentage of Participants | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|---|
| Overall Response Rate (ORR) | 32.3 (24.2 to 41.2) | 22.8 (15.7 to 31.2) | 17.2 (11.0 to 25.1) |
Clinical Benefit Rate (CBR) was defined as the percentage of patients with evidence of Complete Response (CR), Partial Response (PR), or maintaining Stable Disease (SD) for at least 6 months while on study, according to the investigator assessment of response per RECIST 1.1 criteria.
| Percentage of Participants | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|---|
| Clinical Benefit Rate (CBR) | 51.6 (42.5 to 60.7) | 43.1 (34.2 to 52.3) | 34.4 (26.1 to 43.6) |
Time to Response (TTR) was defined as the time from randomization to the earliest date of Complete Response (CR) or Partial Response (PR)
| Days | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|---|
| Time to Response | 85.0 (72 to 1031) | 86.5 (65 to 1175) | 86.0 (67 to 337) |
Duration of Response (DOR) was defined as the duration between the date of first documented Complete Response (CR) or Partial Response (PR) and the date of first documented sign of Progressive Disease or Death, or to the date of censor.
| Months | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|---|
| Duration of Response (DoR) | 22.5 (11.1 to 33.1) | 11.1 (5.6 to NA) | 11.8 (5.4 to 28.1) |
Quality of life was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire. It is a 37-item (27 general questions and 10 breast cancer specific questions) self-reporting instrument consisting of 5 dimensions: physical well-being (PWB), social well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and a breast cancer subscale (BCS). The followings were the score ranges for each self-reporting subscale: • PWB : 0-28 • SWB : 0-28 • EWB : 0-24 • FWB : 0-28 • BCS : 0-40 FACT-B Total Outcome Index (TOI) = PWB + FWB + BCS (range:0 - 96) FACT-B Total Score = PWB + SWB + EWB + FWB + BCS (range:0-148) FACT-G Total Score = PWB + SWB + EWB + FWB (range:0-108). For all the FACIT scales and symptom indices, the higher the score the better QoL
| score on a scale | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|---|
| FACT-B total score | -4.2 ± 1.48 | -6.3 ± 1.51 | -2.4 ± 1.51 |
| FACT-G total score | -4.3 ± 1.22 | -5.9 ± 1.24 | -2.8 ± 1.24 |
| FACT-B trial outcome Index (TOI) | -3.3 ± 1.05 | -4.2 ± 1.07 | -0.6 ± 1.07 |
| Physical well-being (PWB) | -2.0 ± 0.48 | -2.1 ± 0.49 | -0.5 ± 0.49 |
| Social family wellbeing (SWB) | -0.5 ± 0.50 | -1.5 ± 0.50 | -0.9 ± 0.51 |
| Emotional wellbeing (EWB) | -0.4 ± 0.40 | -0.6 ± 0.40 | -1.0 ± 0.41 |
| Functional wellbeing (FWB) | -1.3 ± 0.45 | -1.7 ± 0.46 | -0.3 ± 0.46 |
| Breast cancer subscale (BCS) | 0.0 ± 0.47 | -0.5 ± 0.47 | 0.4 ± 0.48 |
Pre-treatment deaths were collected from day of participant's informed consent to the day before first dose of study medication. On-treatment deaths were collected from first dose of study medication to 30 days after last dose of study medication (on-treatment), up to approximately 131 months. Deaths were collected in the post treatment survival follow up from 31 days after last dose of study medication until the end of the study, up to approximately 132 months.
| Participants | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) |
|---|---|---|---|
| Pre-treatment deaths | 0 | 0 | 0 |
| On-treatment deaths | 5 | 8 | 5 |
| Post-treatment deaths | 33 | 37 | 34 |
| All deaths | 38 | 45 | 39 |
Collected over Adverse Events (AEs) were collected from first dose of study medication until the last dose plus 30 days post-treat follow-up, assessed up to approximately 131 months. Deaths were recorded from study start date until end of survival follow-up phase (end of study), assessed up to approximately 132 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | 5/124 (4%) | 27/123 (22%) | 113/123 (91.9%) |
| Lapatinib + Aromatase Inhibitor (AI) | 8/123 (6.5%) | 23/123 (18.7%) | 107/123 (87%) |
| Trastuzumab + Aromatase Inhibitor (AI) | 5/122 (4.1%) | 14/121 (11.6%) | 86/121 (71.1%) |
| Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment) | 33/118 (28%) | — | — |
| Lapatinib + Aromatase Inhibitor (AI) (Post-treatment) | 37/114 (32.5%) | — | — |
| Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment) | 34/116 (29.3%) | — | — |
| Event | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment) | Lapatinib + Aromatase Inhibitor (AI) (Post-treatment) | Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment) |
|---|---|---|---|---|---|---|
| Ejection fraction decreasedInvestigations | 7/123 | 1/123 | 2/121 | — | — | — |
| CellulitisInfections and infestations | 3/123 | 1/123 | 2/121 | — | — | — |
| Urinary tract infectionInfections and infestations | 2/123 | 0/123 | 1/121 | — | — | — |
| HypokalaemiaMetabolism and nutrition disorders | 2/123 | 0/123 | 0/121 | — | — | — |
| Cardiac failureCardiac disorders | 1/123 | 0/123 | 1/121 | — | — | — |
| Cardio-respiratory arrestCardiac disorders | 0/123 | 0/123 | 1/121 | — | — | — |
| AstheniaGeneral disorders | 0/123 | 0/123 | 1/121 | — | — | — |
| AppendicitisInfections and infestations | 0/123 | 0/123 | 1/121 | — | — | — |
| HypercalcaemiaMetabolism and nutrition disorders | 0/123 | 0/123 | 1/121 | — | — | — |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/123 | 0/123 | 1/121 | — | — | — |
| Event | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment) | Lapatinib + Aromatase Inhibitor (AI) (Post-treatment) | Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment) |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 87/123 | 64/123 | 11/121 | — | — | — |
| RashSkin and subcutaneous tissue disorders | 43/123 | 36/123 | 3/121 | — | — | — |
| ParonychiaInfections and infestations | 39/123 | 21/123 | 0/121 | — | — | — |
| NauseaGastrointestinal disorders | 28/123 | 28/123 | 13/121 | — | — | — |
| StomatitisGastrointestinal disorders | 23/123 | 16/123 | 5/121 | — | — | — |
| Aspartate aminotransferase increasedInvestigations | 11/123 | 22/123 | 11/121 | — | — | — |
| Decreased appetiteMetabolism and nutrition disorders | 22/123 | 18/123 | 4/121 | — | — | — |
| ArthralgiaMusculoskeletal and connective tissue disorders | 22/123 | 19/123 | 15/121 | — | — | — |
| HeadacheNervous system disorders | 9/123 | 21/123 | 15/121 | — | — | — |
| Alanine aminotransferase increasedInvestigations | 11/123 | 20/123 | 9/121 | — | — | — |
| Age, Continuous(Years) | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) | Total |
|---|---|---|---|---|
| Mean | 56.9 ± 11.15 | 57.1 ± 9.98 | 54.9 ± 10.10 | 56.3 ± 10.45 |
| Sex: Female, Male(Participants) | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) | Total |
|---|---|---|---|---|
| Female | 124 | 123 | 122 | 369 |
| Male | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) | Lapatinib + Aromatase Inhibitor (AI) | Trastuzumab + Aromatase Inhibitor (AI) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 1 | 3 |
| Asian | 31 | 31 | 32 | 94 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 4 | 3 | 10 |
| White | 89 | 85 | 84 | 258 |
| More than one race | 0 | 2 | 2 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Showing the first 100 of 110 sites across 29 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from May 2011 to primary completion in Mar 2016, 58 months.
Results were first posted in Jul 2019, 3 years 4 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 58 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lapatinib · Trastuzumab